New Drug Delivery Techniques Aim to Improve Overall Drug Performance and Efficacy

Main Category: Pharma Industry / Biotech Industry
Article Date: 10 Mar 2005 - 0:00 PDT


Quantum leaps made in the field of proteomics, genomics and biotechnology are creating revolutionary therapeutics that require equally impressive drug delivery systems in order for patients to derive optimum benefits. This, coupled with patent expirations and subsequent competitive threats from lower priced generics, is compelling pharmaceutical companies to investigate these innovative drug delivery solutions.

"There is now a growing realisation that innovative delivery of drugs would not only increase safety and efficacy levels but also improve the overall performance of the drug," says Technical Insights Research Analyst S. Ravi Shankar from Frost & Sullivan (http://technicalinsights.frost.com).

Advances in drug delivery systems are also expected to offer a host of additional advantages such as ease of administration, increased patient compliance, decreased side effects and cost reduction. Moreover, novel drug delivery techniques are value-added features for which companies can charge a premium due to the increased convenience they provide to patients.

Macromolecular drugs, which are larger compared to conventional therapies, demand superior delivery platforms for greater efficacy. Emerging technologies, such as medicated powders pumped into the skin at supersonic speeds, implanted microchips that deliver precise dosages and nanomolecular transportation systems, are vying for commercial acceptance in a competitive market.

While most blockbuster drugs are in the hands of select pharmaceutical companies, numerous drug delivery companies have also become more proactive in participating in the drug development procedure.

"Drug delivery companies have already started developing their own formulations which they can combine with their drug delivery platforms," observes Mr. Shankar. "This allows them to reduce dependency on the pharmaceutical majors for newer drugs and simultaneously augment market revenue."

While drug delivery plays an important role in enriching drug performance, researchers are concentrating on using delivery as a means to reduce dosage frequency, preferably through non-invasive methods.

"Multiple injections required per week or day could be replaced by once a month dosages or even longer intervals, which would stabilise blood levels of the medication, thereby enhancing treatment outcomes and patient compliance," notes Mr. Shankar.

The oral route is expected to be the most dominant technique, followed by the pulmonary route, which is being explored for the delivery of insulin. Researchers in Italy are developing a customised oral drug release technology, which would provide optimum release profiles for single or combination and soluble or insoluble drugs.

In this technique, there is complete dissolution of the tablet, which enables precise and controlled drug release. Other advantages include high drug loading capability, fine tuned release rates for targeted delivery and content uniformity for more accurate dosing.

In the United Kingdom, a novel delivery technique in the form of drug-eluting beads is being looked into for treatment of liver cancer. The residing time of the drug in the bead matches the local elution profile resulting in sustained and slow release within the target tumour site.

Polymers are also emerging as potential drug delivery routes for the treatment of cancer. Compared to conventional drug delivery practices polymers offer improved efficacy, reduced toxicity and increased patient compliance and convenience.

While the inhalable, buccal, lingual and nasal routes are in nascent stages of development, they are considered essential for effective delivery of biotechnology drugs.

Apart from vaccine delivery and analgesics, the nasal route is likely to be particularly useful for the central nervous system (CNS) applications, since the olfactory region of the nasal cavity could provide a more direct access for targeted drug delivery to the brain.

In the United Kingdom, researchers are developing an intelligent inhaler that automatically responds to breathing patterns for delivering precise doses of the drug. This revolutionary system reduces medication levels and shows immense potential for delivering biological drugs.

Drug Delivery: Analysis of Cutting-Edge Technologies and Trends is part of the Technical Insights Healthcare vertical subscription service, and examines the global trends and developments in novel and emerging oral, parenteral, transdermal, and inhalation drug delivery technologies. It analyses the key technology drivers and evaluates the challenges that must be overcome for each new drug delivery technology to realise its potential. The study also covers advances in product development and regulatory aspects impacting the drug delivery sector. Executive summaries and interviews are available to the press.

If you are interested in an analysis which provides manufacturers, end users, and other industry participants with an overview, summary, challenges, and latest coverage of Drug Delivery: Analysis of Cutting-Edge Technologies and Trends - then send an e-mail to Katja Feick - European Corporate Communications at katja.feick@frost.com with the following information: Full name, Company Name, Title, Contact Tel Number, Contact Fax Number, E-mail. Upon receipt of the above information, an overview will be e-mailed to you.

Drug Delivery: Analysis of Cutting Edge Technologies and Trends
D313

Background

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan, an international growth consultancy, has been supporting clients' expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies includes custom strategic consulting, market intelligence, and management training. Our mission is to forge partnerships with our clients' management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan's network of consultants, industry experts, corporate trainers, and support staff spans the globe with offices in every major country.

Media Contacts:

Katja Feick
Corporate Communications - Europe
P: +44 (0) 20 7915 7856
F: +44 (0) 20 7730 3343
E: katja.feick@frost.com

Danielle White
Corporate Communications - North America
P: 210.247.2403
F: 210.348.1003
E: dwhite@frost.com

Pramila Gurtoo
Corporate Communications - Asia Pacific
DID: (603) 6204 5811
Gen: (603) 6204 5800
Fax: (603) 6201 7402
E: pgurtoo@frost.com

http://www.frost.com
http://www.technicalinsights.frost.com

• Additional
• References
• Citations